FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Volker Heinemann, Alexander Kiani et al.|The Lancet Oncology|2016Cited by 417
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupDominik Paul Modest, Anke Reinacher‐Schick, Ingrid Ricard et al.|Annals of Oncology|2016Cited by 344
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)Volker Heinemann, Ulrich Mansmann, Sebastian Stintzing et al.|European Journal of Cancer|2015Cited by 185